Shelly Pinto
Known title: VP, Finance and CAOCIK: 0001857740
Associated companies
Transaction History
| ALXO | ▼ Sell | Open Market | 573 | $1K | 8/17/2026 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,404 | $3K | 7/1/2026 | View on chart |
| ALXO | ▼ Sell | Open Market | 903 | $2K | 3/19/2026 | View on chart |
| ALXO | ▼ Sell | Open Market | 565 | $1K | 2/18/2026 | View on chart |
| ALXO | ▼ Sell | Open Market | 3,925 | $4K | 1/6/2026 | View on chart |
| ALXO | ▼ Sell | Open Market | 611 | $391 | 8/15/2025 | View on chart |
| ALXO | ▼ Sell | Open Market | 2,011 | $905 | 7/7/2025 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,532 | $659 | 6/30/2025 | View on chart |
| ALXO | ▲ Buy | Grant | 3,000 | $0 | 3/14/2025 | View on chart |
| ALXO | ▼ Sell | Open Market | 550 | $633 | 2/19/2025 | View on chart |
| ALXO | ▼ Sell | Open Market | 2,221 | $4K | 1/6/2025 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,426 | $2K | 12/30/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 564 | $1K | 8/14/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,823 | $10K | 7/5/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,373 | $8K | 7/1/2024 | View on chart |
| ALXO | ▲ Buy | Grant | 15,000 | $0 | 2/14/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 2,717 | $37K | 1/4/2024 | View on chart |
| ALXO | ▼ Sell | Open Market | 1,631 | $25K | 12/29/2023 | View on chart |
| ALXO | ▲ Buy | Grant | 26,000 | $0 | 7/25/2023 | View on chart |
| ALXO | ▼ Sell | Open Market | 7,345 | $48K | 7/6/2023 | View on chart |
| ALXO | ▼ Sell | Open Market | 466 | $3K | 6/30/2023 | View on chart |
| ALXO | ▼ Sell | Open Market | 482 | $5K | 12/29/2022 | View on chart |
| ALXO | ▲ Buy | Grant | 11,000 | $0 | 8/5/2022 | View on chart |
| ALXO | ▲ Buy | Grant | 50,000 | $0 | 1/28/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
ALX Oncology reports positive Phase 2 data for evorpacept
ALX Oncology announced that its Phase 2 ASPEN-06 trial data was published in Nature Medicine. The results indicate durable clinical benefit for evorpacept in HER2-positive gastric cancer. This scientific validation provides new context for the stock, which is currently trading near its 52-week low despite an average analyst target of $4.60.
ALX Oncology reports positive Phase 2 data for evorpacept. ALX Oncology announced that its Phase 2 ASPEN-06 trial data was published in Nature Medicine. The results indicate durable clinical benefit for evorpacept in HER2-positive gastric cancer. This scientific validation provides new context for the stock, which is currently trading near its 52-week low despite an average analyst target of $4.60.